[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kuopio University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":455},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,49,79,108,127,154,180,198,222,245,272,293,318,339,362,397,418],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100629180","parental-emdr-therapy-after-a-babys-stay-in-the-nicu-100629180",false,"NCT07471321","Parental EMDR Therapy After a Baby's Stay in the NICU","Effectiveness of an EMDR Intervention in Reducing Trauma-Related Symptoms Among Parents Following Their Infant's Birth and Neonatal Intensive Care: A Randomized Controlled Trial","EMDR-NICU","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Presence of post-traumatic stress symptoms\n* Eligible to receive EMDR therapy according to clinical assessment\n* Ability to understand study procedures and provide informed consent\n* Sufficient proficiency in the Finnish language to complete study assessments and participate in therapy\n\nExclusion Criteria:\n\n* Acute psychiatric condition requiring immediate specialized treatment (e.g., acute psychosis or severe suicidal crisis).\n* Severe cognitive impairment or neurological condition that would prevent participation in psychotherapy or completion of study assessments.\n* Ongoing trauma-focused psychotherapy at the time of enrollment.\n* Any condition judged by the investigator to interfere with safe participation in the study.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized clinical trial evaluates the effectiveness of eye movement desensitization and reprocessing (EMDR) therapy in reducing symptoms of post-traumatic stress disorder (PTSD). Participants with PTSD symptoms will be randomly assigned in a 1:1 ratio to either immediate EMDR in addition to treatment as usual (EMDR+TAU) or delayed EMDR following an initial treatment-as-usual period (TAU+EMDR). Randomization will be stratified by sex.\n\nPTSD symptoms will be assessed using the PTSD Checklist for DSM-5 (PCL-5) at baseline (T1), after the first treatment period (T2), and after the second treatment period (T3). The primary outcome is PTSD symptom severity measured by the PCL-5 at T2, comparing participants receiving EMDR+TAU with those receiving TAU alone during the first treatment period.\n\nSecondary outcomes include clinically meaningful improvement in PTSD symptoms, defined as a reduction of at least 10 points on the PCL-5, symptom change during the initial treatment-as-usual period, the effect of delayed EMDR, and the durability of the EMDR treatment effect over time.",[27],"Stress Disorders, Post-Traumatic",[29,30,31,32,33,34,35],"Post-Traumatic Stress Disorders","Psychological Trauma","Eye Movement Desensitization and Reprocessing","Parents","Infant, Newborn","Intensive Care Units, Neonatal","Psychotherapy, Trauma Focused","NOT_YET_RECRUITING","2026-03-12",{"date":39,"type":40},"2026-03-13","ACTUAL",{"date":42,"type":21},"2026-03",{"date":44,"type":21},"2027-08",{"name":46,"class":47},"Kuopio University Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100617756","outcomes-based-health-program-for-type-2-diabetes-100617756","NCT07322757","Outcomes-Based Health Program for Type 2 Diabetes","Outcomes-Based Health Program for Improving Care and Outcomes in Patients With Type 2 Diabetes: A Real-World Implementation Study in Primary Care","Inclusion Criteria:\n\n* Type 2 diabetes diagnosed\n* At least one of the following:\n\n  1. diagnosed coronary artery disease,\n  2. diagnosed periferal artery disease,\n  3. diagnosed heart failure,\n  4. diagnosed diabetic renal disease (GFR \\\u003C60 OR uACR ≥ 3 for at least three months),\n  5. diagnosed diabetic retinopathy,\n  6. previous stroke,\n  7. diagnosed atrial fibrillation or atrial flutter,\n  8. age ≥ 55 years and at least two of the following conditions:\n\n     1. smoker\n     2. uses antihypertensive medication or systolic blood pressure \\>140 mmHg or diastolic blood pressure \\> 80 mmHg,\n     3. uses lipid lowering medication or LDL-cholesterol \\> 2.6 or\n     4. BMI \\> 25\n\nExclusion Criteria:\n\n* eGFR \\\u003C 30\n* uACR \\> 200\n* BMI \\> 50\n* heart ejection fraction EF \\\u003C 30\n* active cancer or less than five years from cancer treatment at enrollment\n* blindness in both eyes\n* severe psychotic depression\n* inability to utilize digital applications","35 Years","74 Years",{"count":59,"type":21},200,[24],"Type 2 diabetes is a growing health concern worldwide, influenced by genetic factors, overweight, metabolic syndrome, and insufficient physical activity. Good treatment and glycemic control can reduce or delay diabetes-related complications, which account for a significant and increasing share of healthcare costs in Finland. Much of this cost growth is due to complications resulting from inadequate diabetes care. Secondary prevention programs can therefore provide both health and economic benefits. Lifestyle interventions are one way to improve type 2 diabetes care and reduce complications.\n\nThis study aims to evaluate the impact of a digital lifestyle intervention combined with optimized care on treatment and outcomes among adults with type 2 diabetes at high risk for complications.\n\nThe intervention includes access to the BitHabit \"Small Actions\" application, which supports healthy lifestyle changes, and for participants with a body mass index (BMI) over 30, the Onnikka weight management application. The study will be conducted in North Savo, Finland, using a case-control design. Approximately 120 participants will receive the intervention and 50-100 will serve as controls. All participants will have their care plans reviewed and updated according to the Finnish Current Care Guidelines for Type 2 Diabetes. Control group participants will receive standard care, while the intervention group will receive standard care plus the digital tools. The study also includes the validation of the PAID (Problem Areas in Diabetes) questionnaire for use in Finland and in the Finnish language.\n\nThe study duration for each participant is 12 months. Data will be collected through physiological measurements, laboratory tests, questionnaires, and app usage logs. Measurements and questionnaires will be conducted at baseline and after 12 months. The analyses will describe the phenomenon, its prevalence, and associations between variables, as well as potential dependencies.",[63],"Type 2 Diabetes",[65,66,67,68,69],"Type 2 diabetes","High-risk type 2 diabetes patients","Digital lifestyle intervention","PROM","PAID","RECRUITING","2025-12-22",{"date":73,"type":40},"2026-01-07",{"date":75,"type":40},"2025-04-10",{"date":77,"type":21},"2027-12",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":48},"100587884","carpal-tunnel-release-efficacy-trial-100587884","NCT06934187","Carpal Tunnel Release Efficacy Trial","eFficacy Of Carpal tUnnel releaSe (FOCUS) - Protocol for Randomised Controlled Multicentre Triple-Blinded Placebo Surgery Carpal Tunnel Release Trial With Observational Group","FOCUS","Inclusion Criteria:\n\n* CTS diagnosed with ENMG, Symptoms typical for CTS, Ability to understand and answer the questionnaires, ≥ 18 years old.\n\nExclusion Criteria:\n\n* Recurrent CTS; Ongoing systematic steroid treatment, chemotherapy, or immunomodulatory treatment; Pregnancy or breast feeding; Intrinsic muscle atrophy; Peripheral neuropathies; and Profound cognitive impairment",{"count":88,"type":21},96,[24],"Background Carpal tunnel syndrome (CTS) is a prevalent condition that affects 2.7% of the population, especially women. It arises due to compression of the median nerve in the wrist and is linked to factors like diabetes, obesity, and physical workload. Non-surgical treatments such as splinting and corticosteroid injections are often the first approach for mild to moderate CTS but show mixed long-term results. Surgical intervention, carpal tunnel release (CTR), is frequently necessary and has a success rate of 75-88%. CTR is a safe procedure, but like any surgery, it carries risks, including scarring and nerve injury.\n\nRationale Despite its widespread use, the effectiveness of CTR surgery has not been rigorously tested through randomised controlled trials (RCT) against placebo. This leaves a critical gap in understanding whether observed improvements result from surgery or the natural course of CTS, which can sometimes resolve on its own. Previous RCT in hand surgery have faced methodological issues, emphasising the need for high-quality research to validate the benefits of CTR surgery.\n\nObjectives\n\nFOCUS (eFficacy Of Carpal tUnnel release) trial, aims to provide robust evidence of CTR's effectiveness compared to placebo. The null and alternative hypotheses of the trial are as follows:\n\n* Null Hypothesis: The treatment effect of CTR is not superior to placebo surgery.\n* Alternative Hypothesis: The treatment effect of CTR is superior to placebo surgery\n\nTrial Design This multinational, triple-blinded RCT includes two groups: one receiving CTR and the other undergoing placebo surgery. An additional observational cohort will enhance the trial's generalisability. Recruitment begins in Finland, with plans to expand to Denmark, China and Australia. Experienced hand surgeons will perform all procedures, and the study adheres to rigorous international guidelines (SPIRIT).\n\nMethods Eligible participants are screened and randomised 1:1 to receive either CTR or placebo surgery. In CTR, surgeons relieve pressure on the median nerve through a small incision. Placebo surgery involves a similar incision without addressing the nerve compression. Both procedures use the same pre- and post-operative care protocols to maintain participant blinding.\n\nData collection involves comprehensive patient assessments at six months, one, two, and five years. A validated tool, the 6-CTS scale, is the primary outcome measure, while secondary measures include nerve conduction tests, hand strength, and patient-reported satisfaction.\n\nThe study includes 96 participants, allowing for statistical analysis with 80% power to detect meaningful differences in outcomes.Trial is triple-blinded ensuring that participants, outcome assessors, and investigators remain unaware of treatment assignments, minimising bias. Patients will be randomly assigned to 1:1 parallel groups using an internet-based randomisation program.\n\nEthical considerations The trial complies with the Declaration of Helsinki and national regulations. Participants provide informed consent and can withdraw at any time.\n\nData Management and Safety Data is securely stored in compliance with GDPR, and interim analyses are conducted to monitor safety. An independent Data Safety and Monitoring Committee (DSMC) oversees the trial, reviewing any serious adverse events.\n\nExpected Outcomes and Significance\n\nDiscussion The trial seeks to determine whether CTR surgery provides superior outcomes compared to placebo, addressing a critical gap in evidence for this common procedure. By including patient-reported outcomes and rigorous blinding, the study emphasises improvements that matter most to individuals with CTS.\n\nThis research has far-reaching implications for patients, surgeons, and policymakers, offering insights into the value of CTR surgery. The results could refine treatment guidelines, ensuring that surgical interventions are evidence-based and benefit those most in need.\n\nConclusion The FOCUS-trial represents a significant step forward in validating the effectiveness of CTR surgery. By setting a high standard for surgical research, it aims to provide clarity on a widely performed procedure, contributing to improved care and outcomes for individuals with CTS worldwide.",[92,93],"Carpal Tunnel Syndrome (CTS)","Carpal Tunnel Surgery",[95,96,97,98,99],"Carpal tunnel syndrome","Carpal tunnel release","Placebo surgery","Sham surgery","Randomized controlled trial","2025-09-15",{"date":102,"type":40},"2025-09-19",{"date":104,"type":21},"2026-01",{"date":106,"type":21},"2033-12",{"name":46,"class":47},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":48},"100491641","motivational-multicomponent-lifestyle-interventions-as-a-supportive-treatment-for-depression-in-primary-health-care-100491641","NCT05681767","Motivational Multicomponent Lifestyle Interventions as a Supportive Treatment for Depression in Primary Health Care","DEPKuopio","Inclusion Criteria:\n\n* adults ≥ 18 years\n* depression (ICD-10, F32-F33)\n* Beck Depression Inventory (BDI-1A) ≥ 10 points\n* the initiation of treatment in a primary health care center\n\nExclusion Criteria:\n\n* bipolar disorder\n* psychosis\n* substance abuse\n* pregnancy or lactation\n* a long-term rehabilitative psychotherapy.",{"count":116,"type":21},210,[24],"The investigators aim to examine whether a motivational multicomponent lifestyle intervention as a supportive treatment for depression has a beneficial effect on recovery from depression in a primary health care setting.",[120],"Depression",{"date":102,"type":40},{"date":123,"type":40},"2022-11-21",{"date":125,"type":21},"2026-12-31",{"name":46,"class":47},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":48},"100467870","carpal-tunnel-release-under-local-anaesthesia-with-or-without-distal-median-nerve-block-100467870","NCT05372393","Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block","Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block - a Protocol of a Double Blinded Randomised Controlled Trial","PERSONNEL","Inclusion Criteria:\n\n* ≥18 years of age\n* CTS verified by nerve conduction studies\n* Symptoms suitable for CTS\n\nExclusion Criteria:\n\n* Recurrent CTS\n* Peripheral neuropathies\n* Known allergy to the trial drugs\n* Profound cognitive impairment\n* Pregnancy",{"count":136,"type":21},118,[24],"Carpal tunnel syndrome (CTS) is the most commonly appearing entrapment neuropathy of the upper extremity. Treatment options include both non-operative and operative methods. Surgical treatment, carpal tunnel release (CTR), involves division of the transverse carpal ligament. Surgery can be performed under axillary or intravenous block, or general anaesthesia. There are no prior randomised controlled trials (RCT) comparing local infiltration anaesthesia to local infiltration anaesthesia augmented with a distal median nerve block in CTR.\n\nThe aim of this trial is to investigate whether adding a distal median nerve block to local anaesthesia reduces the patient's perceived pain level for up to 72 hours after CTR, compared to using only local anaesthesia, i.e., an anaesthesia mixture injected solely in and around the planned incision and nerve release. The null hypothesis is that the use of distal median nerve block with local anaesthesia does not reduce pain after CTR compared to pure local anaesthesia.\n\nPERSONNEL (carPal tunnEl ReleaSe lOcal iNfiltratioN mEdian bLockade) is a double-blinded, i.e., patient and investigators, RCT in patients with CTS. Patients will be randomly divided into two parallel trial groups, 1:1 in size to each other. Fifty-nine patients will be needed for each group to have adequate power. The primary outcome is the pain level perceived by the patient after the procedure during the first 72 hours using the Visual Analogue Scale (VAS). Secondary outcomes include patient-rated outcome measures, safety, the entire consumption of pain killers after the surgery during the first 72 hours postoperatively, pain of performing the anaesthesia, and pain during and after the operation.\n\nNo trial comparing local anaesthesia to local anaesthesia augmented with distal median nerve block has been published before. There is also no trial noting individual tolerance to pain. The quality of the median nerve block at the wrist has been achieved by using sensory or sensory-motor nerve stimulation and has been proven effective. This increases trust in the effectiveness of the treatment method, but it still needs to be adequately proven which is the goal of this trial.",[140],"Carpal Tunnel Syndrome",[142,143,144,145,146,147],"carpal tunnel syndrome","carpal tunnel release","local anaesthesia","surgery","wide-awake local anaesthesia with no tourniquet","nerve block",{"date":102,"type":40},{"date":150,"type":40},"2022-09-21",{"date":152,"type":21},"2026-04",{"name":46,"class":47},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100540768","high-flow-nasal-cannula-weaning-in-acute-bronchiolitis-100540768","NCT06321133","High Flow Nasal Cannula Weaning in Acute Bronchiolitis","High Flow Nasal Cannula Weaning in Acute Bronchiolitis - an Open-label Randomized Controlled Trials","Inclusion Criteria:\n\n* Clinically diagnosed acute bronchiolitis\n* High flow nasal cannula treatment has lasted for at least 12 hours\n* Measured saturation 95 or more with room air\n* High flow rate is maximum 2l\u002Fkg\u002Fmin\n* The treating doctors considers the infant suitable to be without high flow\n\nExclusion Criteria:\n\n* Major congenital anomaly of lungs, hearts or diaphragm\n* Bacterial pneumonia\n* Parents do not give consent","0 Months","12 Months",{"count":164,"type":21},50,[24],"The goal of this clinical study is to compared two different strategies to end high flow nasal cannula treatment in acute bronchiolitis. This study compared the immediate ending of high flow treatment to weaning strategy, in which the flow rate is gradually decreased. The aim is to assess if the immediate ending shortens the hospitalization time and whether it is a safe strategy.",[168],"Acute Bronchiolitis",[170],"Acute bronchiolitis","2025-08-26",{"date":173,"type":40},"2025-09-03",{"date":175,"type":40},"2024-02-13",{"date":177,"type":21},"2028-12-31",{"name":46,"class":47},4,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":195,"leadSponsor":197,"locationsCount":48},"100464365","non-invasive-neurostimulation-as-a-tool-for-diagnostics-and-management-for-neurodegenerative-diseases-100464365","NCT05326750","Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases","Inclusion Criteria:\n\n* Mild Cognitive Impairment due to Alzheimer's disease\n* Dementia with Lewy Bodies\n* Frontotemporal dementia\n* Idiopathic normal pressure hydrocephalus (iNPH)\n\nExclusion Criteria:\n\n* History of seizures\n* Pregnancy\n* Metal implants in the head (except dental fillings)\n* Electronic implants (i.e. pace-maker, implanted medical pump)\n* Age \\\u003C18 years",{"count":59,"type":21},[24],"Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.",[190,191,192],"Alzheimer Disease","Frontotemporal Dementia","Dementia With Lewy Bodies",{"date":173,"type":40},{"date":123,"type":40},{"date":196,"type":21},"2032-07",{"name":46,"class":47},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":208,"studyType":209,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":48},"100581456","kuopio-lutetium-177-study-in-patients-with-psma-positive-metastatic-prostate-cancer-100581456","NCT06850545","Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer","KuPSMALu","Inclusion Criteria:\n\n1. The patient must sign informed consent to participate in the study.\n2. Patients must be over 18 years of age.\n3. Patients must have histologically confirmed metastatic prostate adenocarcinoma. Histological samples may show neuroendocrine features, but the primary component must be adenocarcinoma.\n4. Patients must have metastatic castration-resistant prostate cancer (mCRPC) that has been treated with at least docetaxel and abiraterone or enzalutamide, or the patients must have declined chemotherapy or be ineligible for docetaxel-based chemotherapy due to contraindications.\n5. Patients must have an adequate performance status: WHO 0-2.\n6. Castration must have been achieved either chemically (LHRH analog or antagonist) or surgically (orchiectomy). Castration is defined as a low testosterone level (S-testosterone ≤ 1.7 mmol\u002Fl).\n7. Patients must have PSMA-positive tumor burden detected by 18F-PSMA-PET-CT imaging.\n8. Patients must have adequate renal and liver function (Creatinine \\\u003C 2x upper limit of normal (ULN), ALT and ALP \\\u003C 5x ULN).\n9. Patients' blood counts must be within acceptable levels (Hb ≥ 100 g\u002Fl, Platelets ≥ 100 x 10⁹\u002FL, Leukocytes ≥ 3.0 x 10⁹\u002FL, or Neutrophils ≥ 1.0 x 10⁹\u002FL).\n10. The expected survival must be more than 6 months.\n11. Patients with ejaculatory capacity must commit to not donating sperm during the treatments and for 6 months after treatment completion.\n\nExclusion Criteria:\n\n1. Patients whose physical condition and cooperation are insufficient to follow the given instructions.\n2. Patients who do not meet the criteria mentioned in the inclusion criteria.\n3. Patients must not have PSMA-negative tumor burden in the liver. The amount of PSMA-negative tumor burden must not exceed the amount of PSMA-positive tumor burden.\n4. Patients with symptomatic untreated spinal cord compression.\n5. Patients must not have acute hydronephrosis or urinary tract obstruction.\n6. Patients must not have a recurrent infection that impairs functional capacity.","MALE",{"count":207,"type":21},150,"5 Years","OBSERVATIONAL","KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.",[212,213],"Metastatic Prostate Adenocarcinoma","PSMA PET-Positive Castration-Resistant Prostate Cancer","2025-02-22",{"date":216,"type":40},"2025-02-27",{"date":218,"type":40},"2020-01-10",{"date":220,"type":21},"2035-12-31",{"name":46,"class":47},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":48},"100571836","nissen-versus-dor-hiatal-hernia-repair-100571836","NCT06725433","Nissen Versus Dor Hiatal Hernia Repair","NiDor-study: a Randomized Controlled Trial Comparing Nissen and Dor Fundoplication in Hiatal Hernia Repair","NiDor","Inclusion Criteria:\n\n* At least 18 years of age\n* Type II-IV hiatal hernia, confirmed by radiology or endoscopy\n* Scheduled for mini-invasive hiatal hernia repair\n* Emergency mini-invasive surgery for hiatal hernia\n* The informed consent is acquired\n\nExclusion Criteria:\n\n* Recurrent hiatal hernia\n* Need for esophageal lengthening procedure (Collis)\n* Gangrene or need for any resection during (emergency) surgery\n* Need for laparotomy or thoracotomy\u002Fthoracoscopy\n* No written consent",{"count":207,"type":21},[24],"Hiatal hernia can present with a wide range of symptoms. An usual surgical repair technique usually includes Nissen fundoplication, while other procedures are less frequently employed. However, recurrence and reoperation rates remain high. This randomized controlled trial aims to compare the efficacy of Nissen and Dor fundoplication in preventing hiatal hernia recurrence and reducing the risk of reoperation\n\nParticipants undergoing minimally invasive hiatal hernia repair will be randomly assigned to either Nissen or Dor fundoplication. Postoperatively at 12 months, anatomical recurrence rates based on computed tomography scans and symptomatic recurrence rates, anti-reflux medication use, GERD-related quality of life, and dysphagia symptoms will be assessed. A subsequent long-term follow-up study will conducted afterwards utilizing national registry data to evaluate reoperation rates and anti-reflux medication use",[234,235,236],"Hiatal Hernia","Paraesophageal Hernia","Recurrence","2025-02-17",{"date":239,"type":40},"2025-02-19",{"date":241,"type":40},"2025-02-07",{"date":243,"type":21},"2030-01-30",{"name":46,"class":47},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":48},"100572684","surgical-suction-aspirates-fluorescence-measurement-100572684","NCT06736470","Surgical Suction Aspirates Fluorescence Measurement","ATM GBM","Inclusion Criteria:\n\n* Admitted to neurosurgery department for surgical resection of a potential glioma\n* Aged 18 years old or older\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled,,",{"count":253,"type":21},25,"Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. Surgeons use 5-aminolevulinic acid (5-ALA) drug-induced fluorescence to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are used to remove cancerous tissues, but so far the suction aspirate tissues have not been routinely used in tissue detection. This single-center observational study compares experts' visual detection of 5-ALA-induced fluorescence and fluorescence detected from the surgical suction waste. The fluorescence from the suction waste will not be reported back to the surgeon.",[256,257],"Gliomas","High-grade Glioma",[259,260,261,262,263],"aspirate tissue monitoring","high-grade glioma","5-ALA","fluorescence-guided surgery","neurosurgery","2024-12-13",{"date":266,"type":40},"2024-12-16",{"date":268,"type":40},"2023-02-07",{"date":270,"type":21},"2026-01-01",{"name":46,"class":47},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},"100572963","feasibility-of-aspirate-tissue-monitoring-in-neuro-oncological-surgery-100572963","NCT06740097","Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery","ATM GBM INT","Inclusion Criteria:\n\n* Patient admitted to neurosurgery department for surgical resection of a suspected high-grade glioma\n* Patients aged 18 years old or older\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled",{"count":164,"type":21},[24],"Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. Surgeons use 5-aminolevulinic acid (5-ALA) drug-induced fluorescence to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are used to remove cancerous tissues, but so far the suction aspirate tissues have not been routinely used in tissue detection. This multicenter controlled clinical trial investigates the clinical performance and outcomes of a new method for detecting tumor from the suction aspirates in near-real time based on 5-ALA induced fluorescence. The feedback from the aspirate tissue monitor (ATM) is expected to improve the identification of tumors, leading to fewer reoperations and better treatment outcomes.",[283],"High Grade Gliomas",[259,260,261,262,263],{"date":286,"type":40},"2024-12-18",{"date":288,"type":40},"2024-09-30",{"date":290,"type":21},"2028-09-01",{"name":46,"class":47},3,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":48},"100551459","transcranial-alternating-current-stimulation-on-patients-with-delirium-and-critical-illness-delitacs-100551459","NCT06460363","Transcranial Alternating Current Stimulation on Patients with Delirium and Critical Illness (DeliTACS)","Transcranial Alternating Current Stimulation on Patients with Delirium and Critical Illness: a Randomized, Controlled, Double Blind, Proof-of-concept Pilot Study","DeliTACS","Inclusion Criteria:\n\n* Delirium in intensive care and duration of delirium for more than 24 hours. Delirium is defined as 4 or more points on ICDSC and -1 or more points on RASS.\n\nExclusion Criteria:\n\n* Under 18 years of age, pregnancy, delirium tremens, epilepsy or history of seizures any time before first trial intervention, active psychotic disease, infection of central nervous system, acute intoxication, traumatic brain injury, stroke, intracranial bleeding and implanted electronic devices.",{"count":302,"type":21},78,[24],"The goal of this clinical trial is to learn if transcranial alternating current stimulation can shorten the duration of delirium in intensive care setting. The main question it aims to answer:\n\n* Is it possible to shorten the duration of delirium with transcranial alternating current stimulation?\n\nResearchers will compare experimental treatment to sham.\n\nParticipants will receive experimental or sham treatment on maximum of two days depending on their delirium status. Duration of delirium is recorded and reported as \"days alive and free of delirium\".",[306],"Delirium",[306,308,309,310],"Tacs","Brain stimulation","Intensive care","2024-10-02",{"date":313,"type":40},"2024-10-04",{"date":315,"type":40},"2024-09-06",{"date":177,"type":21},{"name":46,"class":47},{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":324,"sex":17,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100545311","anorexia-nervosa-and-brain-in-adolescence-100545311","NCT06380257","Anorexia Nervosa and Brain in Adolescence","Inclusion Criteria:\n\nStudy group: 1) age 16-19 years, 2) BMI below 17.5, 3) diagnosis: anorexia nervosa or atypical anorexia nervosa 4) diagnosed within last two years. Inclusion criteria.\n\nControl group : 1) age 16-19 years, 2) BMI over 19.0, 3) No lifetime obesity (BMI over 30) nor eating disorder.\n\nExclusion Criteria:\n\n1\\) glucose metabolism disorder or any chronic medical disorder, or medicine with possible effects on neurotransmitters, 2) previous mental health problem (excluded anorexia nervosa or atypical anorexia nervosa in study group), 3) smoking, nicotine products, alcohol or any other substance abuse or dependence, 4) contraindication for used brain imaging method.",true,"16 Years","19 Years",{"count":164,"type":21},"Aims of this follow-up study are to investigate effects of anorexia nervosa on brain structure and functions in adolescence.",[330],"Anorexia Nervosa","2024-04-18",{"date":333,"type":40},"2024-04-23",{"date":335,"type":21},"2024-09",{"date":337,"type":21},"2030-12",{"name":46,"class":47},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":346,"minAge":18,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":48},"100505610","open-and-endoscopic-technique-in-female-inguinal-hernia-repair-femalehernia-100505610","NCT05863624","Open and Endoscopic Technique in Female Inguinal Hernia Repair. FemaleHernia","Postoperative Pain and Recurrences After Totally Extraperitoneal Endoscopic (TEP) vs. Lichtenstein Hernioplasty in Female Inguinal Hernia Repair: a Prospective Randomized Multi-center Study","Inclusion Criteria:\n\n* primary inguinal hernia in females\n\nExclusion Criteria:\n\n* emergency operation\n* recurrent hernia\n* groin pain without hernia\n* frail and sick patient ASA ≥ 4","FEMALE","80 Years",{"count":349,"type":21},170,[24],"This randomized study compares open inguinal hernia repair (Lichtenstein hernioplasty) to endoscopic repair (TEP) in terms of chronic pain and recurrences in one and five years after operation.",[353],"Post Operative Pain","2024-03-05",{"date":356,"type":40},"2024-03-06",{"date":358,"type":21},"2024-09-01",{"date":360,"type":21},"2029-12-31",{"name":46,"class":47},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":324,"sex":17,"minAge":370,"maxAge":326,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":383,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":48},"100536294","recognition-and-early-intervention-for-alcohol-and-substance-abuse-in-adolescence-in-adolescent-100536294","NCT06262958","Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence in Adolescent","REAL-SMART: Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence, REAL\u002FSystemic Metabolic Alterations Related to Different Psychiatric Disease Categories in Adolescent","REAL-SMART","Inclusion Criteria: Admitted to the Kuopio University Hospital (KUH) adolescent psychiatric outpatient clinic during the years 2016-2019\n\nExclusion Criteria: Unable to understand the questionnaires","14 Years",{"count":372,"type":21},800,[24],"ASSIST mini-intervention is applied in an electric form in adolescent outpatients to see if it",[376,377,378,379,380,381,382],"Alcoholism","Substance Abuse","Alcohol Dependence","Alcohol-Related Disorders","Substance Use Disorders","Adolescent Behavior","Adolescent Problem Behavior",[384,385,386,387,388],"alcohol","substance","abuse","mini-intervention","adolescent","2024-02-08",{"date":391,"type":40},"2024-02-16",{"date":393,"type":40},"2017-08-07",{"date":395,"type":21},"2030-06-01",{"name":46,"class":47},{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":48},"100367700","cpet-in-myocardial-ischemia-100367700","NCT04067700","CPET in Myocardial Ischemia","Accuracy of Cardiopulmonary Exercise Testing in the Diagnosis of Myocardial Ischemia","Inclusion Criteria:\n\n* Referral to coronary perfusion PET\u002FCT scan in Kuopio University Hospital\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy or breastfeeding\n* Handicap\n* Imprisonment\n* Care under forensic psychiatry",{"count":405,"type":21},100,[24],"The investigators goal is to determine whether cardiopulmonary exercise testing (CPET) can be utilized in the diagnosis of myocardial ischemia. For the study participants the investigators will recruit patients who have been referred to myocardial perfusion PET\u002FCT scan in Kuopio University Hospital. The participants will perform the CPET on a cycle ergometer on separate day after the perfusion scan. The investigators will compare the results of the PET\u002FCT scan and CPET and evaluate if the possible perfusion defects detected in PET\u002FCT correlate with the gas exchange parameters in CPET.\n\nThe patients who receive invasive coronary treatment (coronary bypass surgery or percutaneous coronary intervention) will be invited to perform additional CPET ja PET\u002FCT tests six months after the treatment. The goal will be to determine whether the recovery of myocardial perfusion can be assessed with gas exchange parameters in CPET.",[409],"Myocardial Ischemia","2021-08-04",{"date":412,"type":40},"2021-08-05",{"date":414,"type":40},"2019-10-03",{"date":416,"type":21},"2028-09",{"name":46,"class":47},{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":17,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":436,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":48},"100321850","personalized-activity-intervention-in-rehabilitation-after-cardiac-operations-the-paco-trial-100321850","NCT03470246","Personalized Activity Intervention in Rehabilitation After Cardiac Operations (the PACO Trial)","Personalized Intervention to Increase Physical Activity and Reduce Sedentary Behaviour in Rehabilitation After Cardiac Operations (the PACO Trial)","PACO","Inclusion Criteria:\n\n* An eligible patient with coronary artery disease, aortic valve stenosis or mitral valve insufficiency scheduled for elective coronary artery bypass grafting, aortic valve replacement or mitral valve repair operation.\n* He \u002F she does not have any severe disease or functional limitation limiting PA (other than CVD).\n* He \u002F she is willing to wear a hip- and wrist-worn accelerometer.\n* He \u002F she is willing and capable to use a smart phone application.\n\nExclusion Criteria:\n\n* He \u002F she ends up in prolonged intensive care after cardiac operation.\n* He \u002F she has a memory disorder (i.e. Alzheimer's disease).","30 Years","90 Years",{"count":429,"type":21},540,[24],"The PACO trial is a randomized clinical trial conducted in Heart Centers of Kuopio and Turku university hospitals. The coronary artery disease, aortic valve stenosis and mitral valve insufficiency patients preparing for elective coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or mitral valve repair (MVR) will be randomized to either intervention or control group. The specific operation groups (CABG, AVR and MVR) will be analyzed separately. The 7-day baseline measurements of sedentary behaviour (SB), physical activity (PA) and sleep will be conducted to the patients by using the RM42 accelerometer during the pre-operative month.\n\nAfter the cardiac procedure is completed and the patient is moved to post-operative ward, the control group patients will begin the standard post-operative rehabilitation program of the participating hospitals (activity guidance given by a physiotherapist). Patients in the intervention groups will follow the identical program but after discharge they will also receive personalized activity guidance through the combination of ExSed smart phone application, Suunto MoveSense accelerometer and cloud system during the first 90 days of post-operative rehabilitation. Weekly evolving daily goals to replace SB with PA (daily goals for steps, moderate PA, light PA and standing, and sitting time limit) will be designed for each patient of the intervention groups. A new daily step goal will be delivered from the cloud system to the patient's smart phone in the beginning of each week of the intervention. The daily step goal of the first intervention week is based on patient's walking distance assessed by a physiotherapist in post-operative ward. The following goals will be automatically evolved in the basis of patient's personal average step count of the previous week. The MoveSense accelerometer will measure accumulated levels of SB, PA and sleep, and transmit the data to user's ExSed application with Bluetooth. With information about accumulated levels of SB and PA, the application is able to guide the patient to accomplish the predefined activity goal. The guidance and motivation will be offered with pop-up notifications and histograms (columns are fulfilled according to patient's accumulated daily activity). The researches retain a remote access to the activity data of patients in the cloud system. The ExSed application will be connected to the cloud system with internet connection.\n\nIn addition, the patients of the intervention groups will receive short video files (lasting from 1 to 3 minutes) containing exercise guidance from a physiotherapist specialized to cardiac operation patients. These videos are available on the ExSed application during the intervention. The physiotherapist will also contact each patient (by mobile phone) with structured contact form from 1 to 4 times in a month to make sure that the intervention is proceeding as designed.",[433,434,435],"Coronary Artery Disease","Aortic Valve Stenosis","Mitral Valve Insufficiency",[437,438,439,440,441,442,443,444,445,446],"Accelerometer","Aortic valve replacement","Aortic valve stenosis","Coronary artery bypass grafting","Coronary artery disease","eHealth","Interactive guidance","Mitral valve insufficiency","Mitral valve repair","Rehabilitation","2019-08-14",{"date":449,"type":40},"2019-08-15",{"date":451,"type":40},"2018-04-06",{"date":453,"type":21},"2028-03-01",{"name":46,"class":47},""]